Archives: Agenda

• Nootropics are the New Buzz: How brain-boosting ingredients are creating a white space for brands, and what makes nootropics different from other functional claims
• Bridging Science & Storytelling: Practical ways to educate consumers on complex ingredients without losing the ritual and fun of the drinking occasion
• From Ingredient to Icon: What it takes for a mind-enhancing beverage to stand out. Formulation, sourcing, regulatory guardrails, and flavour are all part of the brand promise
• Lessons from Kin: How we’ve navigated brand development, marketing, and community-building around cognitive function
• A Wellness Status Symbol: Why the next generation of drinkers sees cognitive wellness as the ultimate luxury, and how that shifts category strategy for innovators and suppliers alike
• Where We Go Next: What’s on the horizon for brands ready to push beyond mindful drinking into mind-bending territory

• Dives into GLP-1s and how this is changing beverage consumption
• It explores how GLP-1s are driving a shift from alcohol to soft drinks and how this impacts innovation
• Unpacks what innovation needs to look like for GLP-1 consumers – touching on hydration, greater functionality, taste innovation to deliver on consumer experiences

• How pharma can move digital health and digital diagnostics from pilots to scalable real-world solutions
• Key building blocks for adoption, including data, clinical evidence, technology development, and clinical workflow integration
• Practical lessons from real programs across screening, monitoring, and patient-centric digital tools

• Overcoming financial constraints when budgets are limited and resources tight
• Building flexibility into outsourcing partnerships for scalability
• Fierce site competition: How start-ups can compete with established companies for sites
• Utilizing effective planning to improve study and program efficiency without compromising patient safety
• Agile and adaptable: Being prepared to adjust your strategy and approach as needed

Moderator: Keya Watkins, President – Oncology, Worldwide Clinical Trials

Visit our exhibitors’ booths throughout the 2 days and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple devices or Amazon gift cards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!

• Managing increasing regulatory divergence across the US, Europe, and emerging global trial regions
• Understanding the operational impact of evolving FDA expectations and Project Optimus requirements on oncology development programs
• Do sponsors know where the gaps are in the latest ICH-GCP E6(R3) and how can AI help conduct gap analyses across SOPs and study documents
• Assessing the current state of European harmonization, including ongoing challenges around submissions, approvals, and operational consistency across markets

Moderator: Keya Watkins, President – Oncology, Worldwide Clinical Trials

As oncology development grows more complex, CRO partnerships have become central to how programs scale, execute, and deliver. Yet in practice, these relationships are often more nuanced than the traditional value proposition suggests.

In this candid discussion, we’ll explore CRO partnerships from a biotech perspective – examining where they fall short, and what it takes to make them work in real-world settings.

• The strategic upside of CRO partnerships, including scaling with specialized operational and regulatory expertise
• Where partnerships break down, from misaligned expectations to gaps in execution, communication, and accountability
• When a single, integrated CRO model is most effective — and when a more tailored, multi-CRO approach better supports program needs
• What stronger partnerships look like in practice, with a focus on alignment, transparency, and shared ownership of outcomes

How strategic collaboration can accelerate innovation:

• Moving from transactional execution to consultative partnership
• How CROs can become strategic problem solvers, not just service providers
• Building trust transparency and shared accountability

• The factors/barriers for why patients don’t readily participate in clinical trials and how to address them
• Why targeted culturally humble communication is necessary for “marketing” clinical trials
• The benefits of navigation to retain patients
• Success story examples